Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 485

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 485
---
 for the periods presented.

| Direct program costs:                   |     | Three months ended 
 September 30,      
 2024               
 (in thousands)     |       |     | 2023 |       |     | Change |      |   |
|:----------------------------------------|:----|:-------------------|------:|:----|:-----|------:|:----|:-------|-----:|:--|
| IFx-2.0                                 |     | $                  | 1,422 |     | $    | 2,014 |     | $      | (592 | ) |
| Preclinical research costs              |     |                    |   376 |     |      |    73 |     |        |  303 |   |
| Indirect program costs:                 |     |                    |       |     |      |       |     |        |      |   |
| Personnel and facilities related costs  |     |                    | 1,149 |     |      | 1,376 |     |        | (227 | ) |
| Total research and development expenses |     | $                  | 2,947 |     | $    | 3,463 |     | $      | (516 | ) |

Research and development expenses were $3.0 million and $3.5 million for the three months ended September 30, 2024, and 2023, respectively. The decrease of $0.5 million related to the following.

| • |     | a decrease of approximately $0.6 million due to ongoing clinical development of IFx-2.0; |

| • |     | an increase of $0.3 million due to preclinical research of IFx-3.0 and MDSCs; and |

| • |     | a decrease of $0.2 million in facilities, salary and personnel related costs. |

General and Administrative Expenses.General and administrative expenses were $0.8 million and $1.1 million for the three months ended September 30, 2024, and 2023, respectively. The decrease of $0.3 million was primarily due to legal fees associated with the TuHURA Biopharma Inc. asset acquisition and the terminated merger with CohBar, Inc.—all that were incurred in the previous year. 299

Interest Expense.During various dates from December 2023 to September 2024, as part of the TuHURA Note Financing, TuHURA issued convertible